RANIBIZUMAB
ranibizumab 1.65 mg/0.165 mL injection, 0.165 mL syringe
RANIBIZUMAB (13143R)
13143R
Body System:
Manner of administration:Injection
Restriction (Streamlined authority code: 13392)
Indication: Subfoveal choroidal neovascularisation (CNV)
Treatment phase: Continuing treatment
Restriction (Streamlined authority code: 13340)
Indication: Subfoveal choroidal neovascularisation (CNV)
Treatment phase: Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 2 | DPMQ: $786.69 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
|
|
|||||